Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms.
The discovery of the role of PF4 in the development and pathogenicity of heparin-dependent antibodies which trigger heparin-induced thrombocytopenia (HIT), a rare but severe adverse effect of heparin therapy, has allowed us to revisit the diagnosis of this complication and the pathological mechanisms involved. In this review, diagnostic tests available for confirmation or prediction of HIT are analysed, and new diagnostic strategies are discussed. Factors involved in the development of the heparin-dependent immune response in some heparin-treated patients are then presented. Lastly, it is hypothesized that the presence of antibodies is a risk factor for HIT. The mechanisms which contribute to the development of complications and the role of additional risk factors, including the patient's clinical state and the type of heparin used, are discussed (Magnani, 1993).
Amiral
J
J
Hyphen BioMed Research Organization, Franconville, France.
Meyer
D
D
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D019937:Diagnostic Techniques and Procedures; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D010978:Platelet Factor 4 / Q000502:physiology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology
D000925:Anticoagulants; D010978:Platelet Factor 4; D006493:Heparin